First-Quarter 2026 Business Review

Marcy l’Étoile (France), April 23^rd, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026.

• First quarter was impacted by mild respiratory epidemiology, and by the uncertain geopolitical and macroeconomic environment which drives softness in customers’ investment decisions.
• -3.9% organic sales decline in Q1 2026, reflecting a weaker respiratory season compared with the exceptionally strong epidemiology in Q1 2025 (resulting in BIOFIRE^® respiratory panels sales down 23%) and a slow start of the year in instruments sales (-18%) in a soft market for new installations.
• GO•28 growth drivers’ reagents sales up 6.5% organically, notably +31% in SPOTFIRE^® reagents sales and +8% in industrial applications reagents sales.
• Considering the first-quarter performance and the current market dynamics, bioMérieux revises its 2026 full-year guidance:
  • Annual sales are now expected to grow organically between +3% to +5% (versus between +5% and +7% previously);
  • Annual CEBIT is expected to grow organically between 0% and 10% (versus at least +10% previously) excluding a prolonged impact of Middle East events.
• Confirmation of a full‑year CEBIT headwind from currency effect of -€50m to - €60m.

Pierre Boulud, Chief Executive Officer, said: “In Q1 26, we continued to deliver on innovation, with the launch of SPOTFIRE^® mini assays in Europe, the regulatory filing of SpinChip Hs‑troponin assay, the launch of Mycoplasma assay on SPOTFIRE^®, and the acquisition of Accellix for Pharma Quality Control. For 2026, acknowledging the particularly soft market environment that weighed on first‑quarter performance, bioMérieux has revised its full‑year guidance downward. Leveraging our GO•28 initiatives, we will maintain strict and disciplined control of our cost base, to ensure a positive organic evolution of CEBIT in 2026.”